Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort

R Newton; T Ribeiro; D Casabonne; E Alvarez; A Touzé; T Key; P Coursaget

doi:10.1038/sj.bjc.6602869

Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort

Br J Cancer. 2005 Nov 28;93(11):1305-6. doi: 10.1038/sj.bjc.6602869.

Authors

R Newton¹, T Ribeiro, D Casabonne, E Alvarez, A Touzé, T Key, P Coursaget

Affiliation

¹ Epidemiology & Genetics Unit, Department of Health Sciences, Heslington, York, UK. Rob.newton@egu.york.ac.uk

Abstract

In a case-control study nested within the EPIC-Oxford cohort, there were no statistically significant differences in the prevalence or titre of antibodies against BK virus measured in plasma taken prior to diagnosis between cases with cancer of the prostate (n=31), kidney (n=5) or bladder (n=9) and controls (n=45).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Viral
BK Virus / immunology
BK Virus / pathogenicity*
Case-Control Studies
Cohort Studies
Female
Humans
Kidney Neoplasms / virology*
Male
Middle Aged
Polyomavirus Infections / complications
Prostatic Neoplasms / virology*
Tumor Virus Infections / complications
Urinary Bladder Neoplasms / virology*

Substances

Antibodies, Viral